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ABSTRACT
ObjeCtive
To evaluate whether an epidural steroid injection or 
gabapentin is a better treatment for lumbosacral 
radiculopathy.
Design
A multicenter randomized study conducted between 
2011 and 2014. Computer generated randomization 
was stratified by site. Patients and evaluating 
physicians were blinded to treatment outcomes.
settings
Eight military, Veterans Administration, and civilian 
hospitals.
PartiCiPants
145 people with lumbosacral radicular pain secondary 
to herniated disc or spinal stenosis for less than four 
years in duration and in whom leg pain is as severe or 
more severe than back pain.
interventiOns
Participants received either epidural steroid injection 
plus placebo pills or sham injection plus gabapentin.
Main OutCOMe Measures
Average leg pain one and three months after the 
injection on a 0-10 numerical rating scale. A positive 
outcome was defined as a ≥2 point decrease in leg 
pain coupled with a positive global perceived effect. 
All patients had one month follow-up visits; patients 
whose condition improved remained blinded for their 
three month visit.
results
There were no significant differences for the primary 
outcome measure at one month (mean pain score 3.3 
(SD 2.6) and mean change from baseline −2.2 (SD 2.4) in 
epidural steroid injection group versus 3.7 (SD 2.6) and 
−1.7 (SD 2.6) in gabapentin group; adjusted difference 
0.4, 95% confidence interval −0.3 to 1.2; P=0.25) and 
three months (mean pain score 3.4 (SD 2.7) and mean 
change from baseline −2.0 (SD 2.6) versus 3.7 (SD 2.8) 
and −1.6 (SD 2.7), respectively; adjusted difference 0.3, 
−0.5 to 1.2; P=0.43).  Among secondary outcomes, one 
month after treatment those who received epidural 
steroid injection had greater reductions in worst leg pain 
(−3.0, SD 2.8) than those treated with gabapentin (−2.0, 
SD 2.9; P=0.04) and were more likely to experience a 
positive successful outcome (66% v 46%; number 
needed to treat=5.0, 95% confidence interval 2.8 to 27.0; 
P=0.02). At three months, there were no significant 
differences between treatments.
COnClusiOns
Although epidural steroid injection might provide 
greater benefit than gabapentin for some outcome 
measures, the differences are modest and are 




The physical, socioeconomic, and psychological impact 
of low back pain is enormous. Low back pain has been 
the leading cause of years lost to disability over the past 
several decades,1 with a lifetime prevalence that ranges 
between 50% and 90%.2 3 The economic cost is 
 estimated to exceed $100 bn a year in the United States 
(£67 bn, €93 bn), over half of which can be attributed to 
lost productivity.3 4 Efforts to deal with the worldwide 
burden posed by low back pain have become an inter-
national priority. 
The classification of back pain is perhaps the most 
important distinction for clinicians to make as it influ-
ences investigation and treatment decisions at all levels 
of care.5 Since the development of validated instru-
ments to categorize low back pain,6 7  studies have deter-
mined that the proportion of chronic cases that are 
predominantly neuropathic (that is, sciatica, radicular 
pain from a herniated disc, or neurogenic claudication 
from spinal stenosis) ranges between 17% and 55%,7-11 
with one review finding a median prevalence rate of 
41%.12  Whereas the presence of neuropathic symptoms 
portends a more negative prognosis for acute epi-
sodes,13 lumbosacral radicular pain might be more 
responsive to procedural interventions than non- 
specific back pain.12 14
Epidural steroid injections are the most commonly 
performed procedure for pain relief in the world,15 
being more commonly used and more effective for 
radicular pain than mechanical spine pain.12 16 
Although mixed, most controlled studies have also 
WhAT IS AlReAdy knoWn ABouT ThIS TopIC
Gabapentin and epidural steroid injections are often used to treat lumbosacral 
radiculopathy and can provide benefit for a subset of patients, but we do not know 
which treatment works better
WhAT ThIS STudy AddS
Both epidural steroid injections and gabapentin treatment resulted in significant 
improvements in pain scores and functional capacity
Although epidural steroid injections might be superior to gabapentin in some 
outcome measures, the differences are small and generally short lived
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found pharmacotherapy with gabapentinoids can be 
effective for lumbosacral radicular pain.17-21
Numerous controlled trials have been performed to 
evaluate epidural steroid injections and drug treatment 
in people with low back pain, with review articles gen-
erally reporting modest effects.12 22  Yet for clinicians, the 
more relevant question is not whether a real treatment 
is better than a sham treatment, but which treatment is 
more effective.23
Several small randomized open label studies have 
looked at epidural steroid injections compared with 
drug treatment. One study showed superiority for a sin-
gle epidural steroid injection at one month but not later 
follow-up compared with tramadol and a muscle relax-
ant.24 A second study showed that a single caudal epi-
dural steroid injection provided better pain relief than 
non-steroidal anti-inflammatory drugs through three 
months.25 Neither study evaluated first line adjuvant 
treatments (such as gabapentin) as a comparison 
group. A more recent three armed multicenter study 
was performed in 169 patients with cervical radiculop-
athy. Over six months participants received nortripty-
line and/or gabapentin plus physical therapies, up to 
three cervical epidural steroid injections, or combina-
tion treatment in which they received both injections 
and conservative care. They found that the combination 
group experienced a higher success rate at three 
months but not six months.26 Although these studies 
might simulate real life decisions facing clinicians, the 
fact that none were blinded precludes any conclusions 
regarding efficacy. We investigated a single epidural ste-
roid injection compared with gabapentin in patients 




The study sites were four joint service military treat-
ment facilities, three of which serve as teaching hospi-
tals (Walter Reed, San Diego, and San Antonio) and one 
of which is located in Europe; a Veteran’s Administra-
tion hospital; and three civilian teaching hospitals 
(Johns Hopkins, Case Western, and Penn State).
All participants were treated between 15 December 
2011 and 10 June 2014. Inclusion criteria were age ≥17; 
an average score for radicular leg pain of ≥4 on a 0-10 
numerical rating scale over the preceding week or 3/10 
if the leg pain was as bad as or worse than back pain; 
current symptoms had lasted for more than six weeks 
and up to four years; and signs (such as straight leg 
raising test) and/or symptoms (such as lower leg pain) 
of lumbosacral radicular pain. All participants were 
also required to have findings of a herniated disc or spi-
nal stenosis on magnetic resonance imaging, concor-
dant with their presentation. Patients were permitted 
to have symptoms in more than one dermatome.
Exclusion criteria were neuropathic pain for more 
than four years in duration; previous failed trial with, or 
adverse reaction to, gabapentin or pregabalin; epidural 
steroid injections within the past three years; cauda 
equina syndrome; referrals for surgical evaluation; 
 previous lumbar spine surgery; pregnancy; allergic 
reaction to contrast dye; known secondary gain (such 
as active litigation); active infection; and serious medi-
cal (such as poorly controlled diabetes, cirrhosis, recent 
myocardial infarction, congestive heart failure, or 
unstable angina) or psychiatric condition (such as 
dementia, poorly controlled post-traumatic stress syn-
drome as indicated by a score ≥44 on the post-traumatic 
stress disorder checklist,27  substance abuse, somatiza-
tion disorder, or depression as indicated by a Beck 
Depression score ≥2128) that might preclude an optimal 
response to treatment. Because our intention was to 
evaluate the relative effects of two commonly used 
treatments for radicular pain, we also excluded patients 
with neurogenic claudication from spinal stenosis who 
did not report lower leg pain (that is, those who had 
only weakness or paresthesias). Although heterogene-
ity is often desirable in comparative effectiveness trials, 
we performed briefings, debriefings, full time access to 
a senior investigator, and at one site practice enroll-
ments to enhance selection consistency.
randomization and interventions
We randomized 145 participants in a 1:1 ratio by com-
puter generated randomization tables. An investigator 
physician enrolled participants, stratified by study site. 
Research nurses performed allocation in groups of 36 at 
Walter Reed and Johns Hopkins as these sites were 
expected to enroll more patients, and in groups of 18 at 
other sites, with treatment allocated with a sequentially 
numbered opaque sealed envelope before injection. 
Larger allocation blocks were used to promote alloca-
tion concealment with investigators. Participants at 
each site were suballocated separately on a 1:1 ratio 
based on the type of epidural steroid injection they 
received: those with unilateral pain received unilateral 
transforaminal epidural steroid injections, while those 
with bilateral pain underwent interlaminar epidural 
steroid injections. The patient, research nurse, and 
evaluating physician were blinded to assignment.
epidural injections
A board certified pain medicine physician conducted or 
supervised all procedures using fluoroscopic guidance. 
The segmental level at which the injection was admin-
istered was selected based on signs, symptoms, and 
radiological findings. For interlaminar injections, a 
Tuohy needle was inserted in or near the midline and 
advanced into the epidural space with image guidance 
in the anteroposterior and lateral views by using the 
loss of resistance technique. For transforaminal epi-
dural steroid injections, a 22 gauge spinal needle was 
inserted coaxially into the upper part of the targeted 
foramina with the imagine intensifier positioned in an 
oblique plane. Correct placement was confirmed with 
the injection of contrast, which showed bilateral spread 
for all interlaminar injections and proximal epidural 
uptake for all transforaminal procedures. Once the 
 physician was satisfied with the pattern of contrast spread, 
a solution consisting of 60 mg of depomethylpredniso-
lone +1 mL of 0.25% bupivacaine was administered. 
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For  those who received interlaminar injections, the 
injectate was diluted in normal saline to a volume of 
4 mL; in the transforaminal subgroup, the total volume 
administered was 3 mL. Whereas some physicians rou-
tinely perform multilevel transforaminal injections, we 
limited our procedures to a single level to minimize 
risks because there are no controlled studies validating 
the use of more than one injection and because a well 
placed transforaminal epidural steroid injection gener-
ally spreads to multiple levels.29 30
sham injections and maintenance of blinding
Participants were instructed ahead of time that they 
might or might not experience paresthesias during the 
procedure and were visually shielded from the image 
screen. The same technique (such as trajectory and use 
of multiplanar fluoroscopy) was used for injections 
except in sham injections the needle was positioned 1-2 cm 
proximal to the epidural space into the posterior liga-
ments. A small volume of saline was then injected in 
lieu of contrast, followed by an additional 3 mL to sim-
ulate the injectate. A generic note was entered into the 
medical record without radiographs.
Pharmacotherapy
A central research pharmacy over-capsulated 300 mg 
gabapentin and placebo capsules to appear identical. 
Before each shipment, the capsules were tested to 
ensure potency, or lack thereof for group 2. Titration 
schedules were prepared on a case-to-case basis in 
accordance with standard practice, but dosing targets 
generally ranged from 1800 mg/day to 3600 mg/day 
three times a day. Drugs were generally up-titrated over 
a period of 15 to 24 days, with the only caveat being that 
a therapeutic dose range had to be obtained at least five 
days before follow-up.
Co-interventions, outcome measures, follow-up, 
and missing data
No contact with the investigative team was permitted 
during the study. Tramadol and non-steroidal anti- 
inflammatory drugs could be prescribed on an “as 
needed” basis as rescue medications (or opioids could 
be increased by up to 20% for those taking opioids), but 
no other co-interventions were permitted. Participants 
were provided with instructions on how to taper their 
analgesic drugs based on response. An investigator 
blinded to treatment carried out the first follow-up visit 
one month after the start of treatment. The primary out-
come measure was the average leg pain score on a 0-10 
numerical rating scale recorded at one and three 
months, reflecting the average pain experienced during 
the week before follow-up. Predefined secondary out-
come measures included worst leg pain over the past 
week, average and worst back pain, score on the 
Oswestry disability index (version 2.0, MODEMS, Des 
Plaine, IL),31 adverse effects and complications, reduc-
tion in analgesic drugs (>20% reduction in opioid use or 
complete cessation of non-opioid analgesics), and 
global perceived effect, which was defined as not 
requiring further non-rescue interventions along with 
an affirmative response to the following two state-
ments:32 “My pain has improved/ worsened/stayed the 
same since my last visit” and “I am satisfied/not satis-
fied with the treatment I received and would/would not 
recommend it to others.”
Because patients cannot accurately distinguish 
between neuropathic pain (which is more likely to 
respond to epidural steroid injection and gabapentin)12 33 
and mechanical pain, we separately recorded leg (neu-
ropathic) and back (mechanical) pain scores as surro-
gates. Whereas a small percentage of cases of axial back 
pain might be neuropathic in nature,34  and many forms 
of mechanical pain such as facet arthropathy and 
degenerative disc disease can radiate into the leg,35  val-
idated instruments have shown that leg pain emanating 
from the back is generally indicative of radicular pain.7
The Oswestry disability index is a 10 question survey 
used to assess function in people with low back and/or 
leg pain in which higher scores indicate greater levels of 
disability. The classification of spinal stenosis was made 
if the participant had moderate or severe canal stenosis 
(<12 mm) not attributable to a herniated disc. We assessed 
complications by asking fixed and open ended questions 
one day after injections and at all  follow-up visits. In addi-
tion to individual variables, we predesignated a positive 
composite outcome (that is, successful procedure) to be a 
decrease of ≥2 points in average leg pain score coupled 
with a positive global perceived effect.36
In those individuals who experienced a positive out-
come at one month, the final follow-up occurred at 
three months. In these individuals, in addition to rescue 
medications, the study drug could also be titrated 
upwards. For ethical reasons, those with a negative out-
come at one month left the study “per protocol” to 
receive non-study interventions, which is consistent 
with other randomized interventional studies.26 32 37 38 
We imputed missing data points for pain scores, 
Oswestry disability index, and the composite outcome 
using the “last observation carried forward” method, 
which can underestimate effect sizes when “dropouts” 
occur because of lack of efficacy.39
statistical analysis
We used an intention to treat strategy for all analyses. 
We calculated differences in treatment effects and 95% 
confidence intervals for pain and disability scores with 
analysis of covariance (ANCOVA) adjusting for baseline 
values of outcome measures. An indicator of the treat-
ment group was coded such that positive values favored 
the epidural steroid injection group. No correction was 
prespecified for multiple comparisons. Because of a dif-
ference in sex distribution at baseline, we adjusted post 
hoc analysis of outcomes for sex. We used logistic 
regression models to compare the proportion of patients 
with adverse events in the first month and factors asso-
ciated with binary outcomes in post hoc analysis. We 
used Poisson regression models with robust standard 
errors to analyze adverse event rates. Effectiveness of 
blinding in each treatment group was evaluated by 
using two indices. In the James blinding index40  (range 
0-1), 0 indicates total absence of blinding, 1 indicates 
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complete blinding, and 0.5 indicates completely random 
blinding. In the Bang blinding index41 (range −1-1), −1 
indicates that all patients guessed the incorrect treat-
ment, 0 indicates all patients randomly guessed, and 1 
indicates all patients guessed the correct treatment. We 
conducted subgroup analyses to ascertain which demo-
graphic and clinical variables were associated with out-
come. Variables examined included etiology (such as 
stenosis v herniated disc), level of injection, pain dura-
tion ≥3 months, injection type (for instance, transfo-
raminal epidural steroid injection for unilateral pain 
v interlaminar epidural steroid injection for bilateral 
pain), smoking status, military status, presence of psy-
chiatric disease, obesity, age, sex, and gabapentin dose. 
We had intended to examine the effect of inciting events 
related to war, such as traumatic brain injury, but there 
were too few patients to render any analysis meaningful. 
We used Bonferroni-corrected significance thresholds 
for post hoc subgroup analyses, with corrected P values 
calculated as 0.05 divided by the number of compari-
sons being made. All other reported P values were based 
on two sided tests, with <0.05 considered significant.
The study was powered to evaluate the effectiveness 
of epidural steroid injections compared with gabapen-
tin. Assumptions include a difference of 1 point in pain 
scores between groups at one month, standard devia-
tion of each group of 2 based on data from previous 
studies, a retention rate of 87%, and a two sided α level 
of 0.05. Although a 30% or 2 point decrease in pain has 
been shown to represent a clinically meaningful benefit 
to an individual patient, the same IMMPACT (Initiative 
on Methods, Measurement and Pain Assessment in 
Clinical Trials) guidelines note that smaller differences 
between groups can be considered to be clinically 
important in clinical trials.36 We chose a 1 point differ-
ence in pain scores because it is consistent with US 
Food and Drug Administration requirements for 
approval of adjuvant analgesic drugs for low back pain 
and gabapentin for neuropathic pain.42 43
Patient involvement
Although non-scientists from the surrounding commu-
nities served on many of the approving review boards at 
participating institutions, patients did not participate 
in the design of this study. All participants will receive 
the results of the study and a copy of the final manu-
script from their study team by email or post.
Results
We assessed 348 potential participants, of whom 147 
were eligible for inclusion and agreed to participate. Of 
these, 145 were assigned to receive either an epidural 
steroid injections and sham drug (n=73) or gabapentin 
and a sham injection (n=72). The two groups were simi-
lar with respect to baseline characteristics, except that 
the epidural steroid injection group contained more 
women (table 1 , figure).
Outcomes
At one month, both the epidural steroid injection group 
and the gabapentin group experienced improvement in 
table 1 | baseline demographic and clinical characteristics of participants in study of 
epidural steroid injections compared with gabapentin for lumbosacral radicular pain. 






Mean (SD age (years) 43.8 (14.0) 41.7 (11.9)
Women* 25 (34) 13 (18)
Duration of pain:
 <3 months: 11 (15) 15 (21)
 3-<months 26 (36) 27 (38)
 1-3 years 27 (37) 23 (32)
 >3 years 9 (12) 7 (10)
Treatment with opioids:
 None 54 (74) 55 (7)
 <60 morphine equivalents/day 16 (22) 14 (19)
 ≥60 morphine equivalents/day 3 (4) 3 (4)
Mean (SD) oral morphine equivalents among opioid users (mg/day) 28.7 (34.8) 38.5 (53.0)
Diagnosis:
 Herniated nucleus pulposus 63 (85) 65 (90)
 Spinal stenosis 10 (14) 7 (10)
Active duty military:
 Any 38 (52) 41 (57)
 Enlisted 26 (36) 30 (42)
 Officer 12 (16) 11 (15)
Inciting event:
 None 42 (58) 41 (60)
 Motor vehicle crash 1 (1) 1 (1)
 Fall 5 (7) 9 (13)
 Lifting 13 (18) 6 (8)
 Sports/training 8 (11) 13 (18)
 Other† 4 (6) 2 (3)
Pain related to deployment 10 (14) 6 (8)
Current smoker‡ 15 (21) 13 (18)
Obesity 13 (18) 19 (26)
Psychiatric comorbidity:
 None 56 (77) 49 (68)
 Mood 9 (12) 12 (17)
 Anxiety 7 (10) 6 (8)
 Substance abuse 3 (4) 4 (6)
 Post-traumatic stress disorder 1 (1) 4 (6)
 Other§ 1 (1) 3 (4)
 Multiple diagnoses 4 (6) 6 (8)
Injection approach:
 Interlaminar 11 (15) 12 (17)
 Transforaminal 62 (85) 60 (83)
Level of injection:
 L2-3 1 (1) 0
 L3-4 1 (1) 2 (3)
 L4-5 22 (30) 18 (25)
 L5-S1 44 (60) 46 (64)
 S1 5 (7) 6 (8)
Mean (SD) baseline pain scores¶:
 Average leg pain 5.4 (2.1) 5.4 (1.9)
 Worst leg pain 7.9 (1.7) 7.8 (2.0)
 Average back pain 5.0 (2.6) 4.7 (2.4)
 Worst back pain 7.0 (2.6) 7.0 (2.9)
 Oswestry disability score 39.8 (15.3) 39.8 (14.7)
*Significant difference between two groups (P=0.027 by χ2 test). 
†Includes post-surgical, pregnancy, spinal tap, and work related. 
‡Includes three participants who chew tobacco products.
§Includes attention deficit hyperactivity disorder and obsessive compulsive disorder.
¶Based on 0-10 numerical rating scale scores.
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the average leg pain score (mean 3.3 points (SD 2.6) and 
mean change from baseline −2.2 points (SD 2.4) in epi-
dural steroid injection group versus 3.7 points (SD 2.6) 
and −1.7 points (SD 2.6) in gabapentin group), but no 
significant difference between groups was observed 
(adjusted difference 0.4 points, 95% confidence interval 
−0.3 to 1.2; P=0.25) (table 2). At three months, improve-
ments in average leg pain score persisted (mean 3.4 
points (SD 2.7) and −2.0 points (SD 2.6) versus mean 3.7 
points (SD 2.8) and −1.6 points (SD 2.7), respectively), 
but again with no significant difference between groups 
(0.3 points, −0.5 to 1.2; P=0.43).
For secondary outcome measures, there were small 
differences between groups favoring epidural steroid 
injections at one month for worst leg pain score 
(adjusted difference 0.9 points, 95% confidence interval 
0.0 to 1.9; P=0.04 (table 2 )) and successful outcome 
(66% and 46%, P=0.02 (table 3 ); number needed to 
treat 5.0, 95% confidence interval 2.8 to 27.0). For aver-
age back pain at one month, there was a moderate 
improvement for the epidural steroid injections group 
(−1.5, SD 1.9) and a mild improvement for the gabapen-
tin group (−1.1, SD 2.3), but the differences were not sig-
nificant (adjusted difference 0.3 points, −0.4 to 0.9; 
P=0.45) (table 2). No significant differences were 
observed for outcomes at three months or for patients 
proceeding to surgery within one year of enrollment (9 
(13%) in epidural steroid injection group v 10 (15%) in 
gabapentin group; P=0.73) (table 3).
Factors associated with outcome and post hoc 
analyses
In subgroup analyses, military officers were more likely 
to experience a positive outcome than either enlisted 
Allocated to receive gabapentin
and  sham injection (n=72)
Allocated to receive epidural steroid
injection and placebo gabapentin (n=73)
Completed assessment and
included in analysis (n=72)
Completed assessment and
included in analysis (n=71)
Completed 3 month assessment and
were included in analysis (n=32)
Completed 3 month assessment* and
were included in analysis (n=41)
Received treatment (n=72):
  Interlaminar approach (n=12)
  Transforaminal approach (n=60)
* Includes eight participants with early 3 month evaluations because of return of pain to baseline level
† Includes one participant who sought emergency care and one with unstable angina who was started on opioids,
   both unrelated to treatment
Received treatment (n=73):
  Interlaminar approach (n=11)
  Transforaminal approach (n=62)
Patients assessed for eligibility (n=348)
Randomized (n=145)
Did not receive treatment (n=0)Did not receive treatment (n=0)
Lost to follow-up (n=0)Lost to follow-up (n=2)
Had negative outcome
and exited study† (n=39)
Withdrew from study (n=0)
Lost to follow-up (n=1)
Had negative outcome
and exited study (n=23)
Withdrew from study (n=7)
Lost to follow-up (n=0)
Excluded (n=203):
  Failed to meet inclusion and/or exclusion criteria (such as previous surgery, no MRI
    correlation, long duration of pain, coexisting medical or psychiatric conditions) (n=127)
  Eligible but declined to participate (n=74)










Flow of progress of participants through clinical trial of epidural steroid injections and 
gabapentin in people with lumbosacral radicular pain
table 2 | Outcomes related to pain and disability in people with lumbosacral radicular pain according to treatment with epidural steroid injections or 
gabapentin*
















 Baseline 73 5.4 (2.1) — 72 5.4 (1.9) — — —
 1 month 73 3.3 (2.6) −2.2 (2.4) 72 3.7 (2.6) −1.7 (2.6) 0.4 (−0.3 to 1.2) 0.25
 3 months 73 3.4 (2.7) −2.0 (2.6) 72 3.7 (2.8) −1.6 (2.7) 0.3 (−0.5 to 1.2) 0.43
Worst leg pain:
 Baseline 73 7.9 (1.7) — 72 7.8 (2.0) — — —
 1 month 73 4.9 (3.1) −3.0 (2.8) 72 5.8 (3.0) −2.0 (2.9) 0.9 (0.0 to 1.9) 0.04
 3 months 73 5.2 (3.4) −2.7 (3.2) 72 5.5 (3.4) −2.3 (3.5) 0.3 (−0.7 to 1.4) 0.54
Average back pain:
 Baseline 73 5.0 (2.6) — 72 4.7 (2.4) — — —
 1 month 73 3.5 (2.6) −1.5 (1.9) 72 3.6 (2.6) −1.1 (2.3) 0.3 (−0.4 to 0.9) 0.45
 3 months 73 3.9 (2.7) −1.1 (2.4) 72 3.7 (2.5) −1.0 (2.4) −0.1 (−0.8 to 0.6) 0.85
Worst back pain:
 Baseline 73 7.0 (2.6) — 72 7.0 (2.9) — — —
 1 month 73 5.1 (2.9) −1.9 (2.4) 72 5.4 (3.2) −1.6 (2.6) 0.3 (−0.4 to 1.1) 0.38
 3 months 72 5.6 (3.2) −1.4 (2.9) 72 5.6 (3.1) −1.4 (2.8) 0.0 (−0.8 to 0.9) 0.91
Oswestry disability score‡:
 Baseline 73 39.8 (15.3) — 72 39.8 (14.7) — — —
 1 month 73 32.6 (18.3) −7.3 (12.5) 72 29.6 (16.0) −10.2 (14.5) −2.9 (−7.2 to 1.3) 0.18
 3 months 73 33.6 (19.4) −6.2 (15.8) 72 29.6 (16.3) −10.2 (16.7) −3.9 (−9.0 to 1.1) 0.12
*Data for missing 1 month and 3 months outcomes including pain scores, Oswestry disability scores imputed by last observed outcome carried forward. Numerical rating scores for pain are 
based on 0-10 numerical rating scales, with 0 indicating no pain and 10 indicating severe pain.
†Differences for pain and Oswestry disability scores adjusted for baseline values. Negative coefficients favor gabapentin group. Positive coefficients favor epidural steroid injection group.
‡10 question survey used to assess function in people with low back and/ or leg pain, in which higher scores indicate greater levels of disability.26
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personnel or non-service members at one month (odds 
ratio 6.7, 95% confidence interval 1.8 to 24.6; P=0.004). 
Injection at S1 was associated with a greater reduction 
in leg pain than at other levels (−0.7, −0.1 to −1.2; P=0.02) 
but failed to reach significance when we adjusted for 
multiple comparisons. We found no associations 
among the primary or composite outcomes at one 
month based on etiology (such as stenosis v herniated 
disc), pain duration ≥3 months, injection type (transfo-
raminal epidural steroid injections for unilateral pain v 
interlaminar epidural steroid injections for bilateral 
pain), smoking status, presence of psychiatric disease, 
obesity, age, sex, or dose of gabapentin. In post hoc 
adjustments for sex, the difference between groups in 
reduction of worst leg pain favoring epidural steroid 
injections was no longer significant (0.3, −0.8 to 1.4; 
P=0.05).
adverse events
The proportion of patients reporting one or more 
adverse events from the injection was 8% (n=6) in the 
epidural steroid injection group and 10% (n=7) in the 
gabapentin group (P=0.75). The proportion of patients 
reporting one or more adverse events from drug treat-
ment was 42% (n=30) in the epidural steroid injection 
group and 51% (n=37) in the gabapentin group (P=0.24; 
table 4).
blinding
We assessed blinding at two time points: immediately 
after the procedure to assess blinding for real epidural 
steroid injections and at the first follow-up to ensure 
blinding for real gabapentin. Immediately after the 
baseline procedure, patients were unaware of assigned 
treatments (James blinding index 0.75, 95% confidence 
interval 0.69 to 0.80; P=1.0; Bing blinding index 0.07 
(−0.07 to 0.21) in the epidural steroid injections group 
and −0.24 (−0.38 to −0.09) in gabapentin group), 
 indicating successful blinding. At one month, the over-
all success of blinding was maintained (James blinding 
index 0.56, 0.49 to 0.63; P=0.93), though there was a 
trend towards better insight into treatment assignment 
for the gabapentin group (Bing blinding index 0.08 
(−0.07 to 0.25) in epidural steroid injection group and 
0.19 (0.03 to 0.36) in gabapentin group).
discussion
Principal findings and study rationale
In people with lumbosacral radicular pain randomized 
to epidural steroid injections or gabapentin, we found 
that although there were some small differences in favor 
of the injections at one month, there were no significant 
differences for our primary outcome measure (average 
leg pain one and three months), and the differences 
observed mostly disappeared at three months. Although 
only a small percentage of our patients had spinal ste-
nosis, our findings are consistent with a recent multi-
center study that found modest short term benefit for 
epidural steroid injections for this condition.44 In our 
study we compared epidural steroid injections with epi-
dural local anesthetic, which a systematic review 
showed was superior to soft tissue control injections 
(that is, not a placebo).45 We elected to use a “true pla-
cebo” (intramuscular injection), which is more difficult 
to blind but unlikely to provide benefit, and included 
patients with both spinal stenosis and herniated disc. 
Broad inclusion criteria enhance generalization and are 
consistent with guidelines on comparative effectiveness 
research.46 47
The rationale for this comparative efficacy study is 
that there are well over 50 published clinical trials epi-
dural steroid injections or adjuvants compared with 
placebo for radiculopathy, but none that compared one 
treatment with another. In accordance with the US 
Department of Health and Human Services recommen-
dation to increase and improve comparative effective-
ness research,46 we decided to compare two of the most 
common treatments for lumbosacral radicular pain in a 
double blind fashion.46
Comparison with other studies
Results of placebo controlled studies evaluating gab-
apentinoids and other membrane stabilizers for radicu-
lopathy are mixed, indicating a probable small effect 
size.48  This suggests that differences between groups 
are unlikely to represent a large treatment effect. 
Although myriad reviews on epidural steroid injections 
have yielded disparate conclusions, recent systematic 
and evidence based reviews have indicated that any 
stand alone treatment effect for epidural steroid injec-
tions is likely to be modest and short lived.12 22
In a recent open label three arm comparative effec-
tiveness study pitting a series of epidural steroid injec-
tions against conservative therapy consisting of 
pharmacotherapy (gabapentin and/or nortriptyline) 
and physical therapy, and the combination of the two, 
it was found that combination treatment with epidural 
steroid injections plus drugs and physical therapy pro-
vided superior benefit to stand alone treatment on some 
table 3 | Further outcomes in people with lumbosacral radicular pain according to 
treatment with epidural steroid injections or gabapentin
epidural steroid 
injection gabapentin






Reduction in drug treatment*:
 4 weeks 67 40 (60) 65 32 (49) 0.23
 12 weeks 40 23 (58) 30 14 (47) 0.37
Global perceived effect (positive)†:
 1 month 73 49 (67) 72 41 (57) 0.21
 3 months 73 33 (45) 72 24 (33) 0.14
Composite outcome (positive)†‡:
 1 month 73 48 (66) 72 33 (46) 0.02
 3 months 73 27 (37) 72 21 (29) 0.32
Proceeded to surgery within year 
of enrollment
72 9 (13) 69 10 (14) 0.73
*Reduction in analgesics corresponds to >20% reduction in opioid use or complete cessation of non-opioid 
analgesics. Patients who were not on pain drugs were excluded from this analysis.
†Missing data for 1 month and 3 months imputed by last observed outcome carried forward.
‡>2 point decrease in average leg pain coupled with positive global perceived effect without additional 
procedural or non-rescue pharmacological interventions.
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outcome measures.26 In some respects, the open label 
format and inclusion of a multimodal treatment 
approach might better reflect “real life” circumstances, 
though they preclude the evaluation of efficacy.
explanation of findings
There are several possible explanations for our find-
ings. The first is that both treatments are equally effec-
tive, but the effects dissipate over time. Unlike studies 
of epidural steroid injections that often follow patients 
for up to one year,49-54  few studies have examined the 
long term effectiveness of gabapentin, but those that 
have indicate that the beneficial effects for neuropathic 
pain are most pronounced early on during treatment.55 
56  A second hypothesis is that neither treatment is effec-
tive, and the benefits observed were caused by a pla-
cebo response or the natural course of the disease. 
Those with chronic radiculopathy, however, are less 
likely than those with shorter duration of symptoms to 
spontaneously improve or respond to treatment.57 
A third possibility is that epidural steroid injections are 
superior to gabapentin, but the relatively small sample 
size, the use of only one injection, treatment blinding, 
and our failure to reinforce the short term benefit with 
physical therapy rendered three month differences 
indistinguishable. In their effectiveness study that com-
pared a series of epidural steroid injections, neuro-
pathic adjuvants plus physical therapy, and 
combination therapy for cervical radiculopathy, Cohen 
and colleagues reported that the better outcomes in the 
combination group might have been attributable to the 
ability of physical therapy to reinforce the short term 
gains afforded by procedures.26
strengths and limitations
The main strength of our study is that we compared 
two of the most commonly used treatments for lumbo-
sacral radiculopathy pain in a double blind fashion at 
institutions that reflect the gamut of settings in which 
patients might seek treatment. There are several lim-
itations to our study, including the primary outcome 
being measured at one month, which was necessary 
because we allowed those with an unsuccessful out-
come to seek other treatments, and the lack of a true 
placebo group, which renders the assay sensitivity 
questionable. Without a true placebo group, one can-
not assess the true efficacy of the two treatments. 
A third limitation is that we did not permit repeat epi-
dural steroid injections or allow combination drug 
treatment. Studies have shown there is little basis for 
a rote “series” of epidural steroid injections, though 
some might benefit from repeat injections, which are 
often performed in clinical practice.12 26 32 44 54 58 59  Sim-
ilarly, randomized studies have shown that combina-
tion treatment with drugs that include gabapentinoids 
could provide superior relief for neuropathic and low 
back pain compared with treatment with a single 
agent.60  A fourth limitation inherent in our design is 
that blinding of participants might have altered our 
findings. “Blinding” is not a tenet of comparative 
effectiveness research, which seeks to determine the 
best treatment in “real world” conditions. The placebo 
effect is especially powerful for subjective measures 
such as pain and stronger for procedures than for pills, 
which might have mitigated any “real world” differ-
ences between treatments.61 62  A final limitation is our 
broad inclusion criteria, which included patients tak-
ing opioids and those with herniated disc and spinal 
stenosis. These conditions are characterized by 
slightly different pathophysiological mechanisms and 
might have different natural outcomes. A larger study 
would be needed to determine whether certain 
patients (such as those with herniated disc versus spi-
nal stenosis) or treatments (transforaminal versus 
interlaminar epidural steroid injections) experience 
better outcomes than others. In practice, patients gen-
erally receive epidural steroid injections and/or adju-
vants regardless of the etiology of their neuropathic 
pain. In clinical trials, most epidural  steroid injection 
table 4 | adverse events in people with lumbosacral radicular pain according to 
treatment with epidural steroid injections or gabapentin. *Figures are numbers 
(percentage) of participants unless stated otherwise
adverse event





Injection received Epidural steroid injections Sham injection —
≥1 event* 6 (8) 7 (10) 0.75
Total adverse events (event rate)† 6 (0.08) 9 (0.13) 0.42
Reported symptoms or events:
 Excessive pain 2‡ 4‡ —
 Fever, infection, or both 2 0 —
 Falls 1‡ 0 —
 Vasovagal 0 2‡ —
 Other§ 1 3 —
related to drug treatment
Treatment received Sham pills Gabapentin pills —
Mean (SD) dose (mg) 2132.9 (609.4) 2095.8 (678.3) 0.73
Compliance¶:
 None 6 (8) 8 (11) 0.68
 Partial (50-89%) 11 (15) 8 (11)
 Full (>90%) 55 (76) 56 (78)
≥1 event*¶ 30 (42) 37 (51) 0.24
Total adverse events (event rate)*¶ 45 (0.63) 50 (0.69) 0.61
Reported symptoms or events¶:
 Sedation/fatigue 8 (11) 13 (18)‡ —
 Cognitive 5 (7) 7 (10)‡ —
 Weight gain 4 (6) 7 (10)‡ —
 Headache 4 (6) 1 (1) —
 Gastrointestinal 13 (18) 8 (11)‡ —
 Swelling 0 (0) 3 (4)‡ —
 Other** 11 (15) 11 (15)‡ —
*Significance assessed with logistic regression model adjusted for treatment group assignment.
†Significance assessed with Poisson regression model with robust standard errors adjusted for treatment group 
assignment.
‡Deemed related to or possibly related to treatment.
§Other adverse events for epidural steroid injection group include “low cortisol noted on lab tests three weeks 
after injection in patient also receiving oral steroids with no symptoms.” Other adverse events for gabapentin 
group (sham injection) include bruising, temporary inability to lift legs, and “GI bleed after three days in patient 
receiving low molecular weight heparin.” None deemed related to treatment.
¶Data missing for one patient in epidural steroid injection group.
**Other adverse events for epidural steroid injection group (placebo pills) include ataxia, balance problems, 
depression, emotionality, kidney stones, muscle twitching, hot flashes, restlessness, rhinorrhea with 
congestion, sexual, vivid dreams, and one without description. Other adverse events for gabapentin group 
include blackout, ‡ depression requiring admission to hospital, dizziness (2), ‡dry mouth (2), ‡leg spasms, mood 
changes, rhinorrhea with flu-like symptoms, and one without description.
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studies12 24–26 32 49 51 53  and all gabapentinoid studies17-21 
included both etiologies, with most studies finding no 
difference in outcomes with epidural steroid injec-
tion12  or gabapentinoid (R Baron, personal communi-
cation, 2014)20 21 between people with stenosis and 
disc herniation.
generalizability
These results are readily generalizable to primary care 
settings, pain clinics, and spine surgery centers, where 
practitioners are often faced with the question about 
the best non-operative way to manage lumbosacral 
radicular pain. Future studies might include both pla-
cebo and combination groups (for example, factorial 
design), allow for multiple injections and drugs, and 
require physical therapy in an effort to determine 
whether any observed benefit could be prolonged. The 
logistical and ethical obstacles in designing such stud-
ies (such as blinding multiple drugs or performing 
multiple sham injections in patients who fail to 
respond to the first one), however, will make them dif-
ficult to execute.
Conclusions and policy implications
Gabapentin and epidural steroid injections used to treat 
lumbosacral radicular pain both resulted in modest 
improvements in pain and function, which persisted 
through three months. Although some differences 
favored epidural steroid injections, these tended to be 
small and transient. The similar outcomes between 
treatment groups on most measures suggest that a trial 
with neuropathic drugs might be a reasonable first line 
treatment option.
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